Cargando…
New drugs to treat tuberculosis
Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370665/ https://www.ncbi.nlm.nih.gov/pubmed/22719795 http://dx.doi.org/10.3410/M4-12 |
_version_ | 1782235145867100160 |
---|---|
author | Swindells, Susan |
author_facet | Swindells, Susan |
author_sort | Swindells, Susan |
collection | PubMed |
description | Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in development of TB diagnostics and therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen development, and the new and repurposed anti-TB agents in clinical development. |
format | Online Article Text |
id | pubmed-3370665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Faculty of 1000 Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33706652012-06-20 New drugs to treat tuberculosis Swindells, Susan F1000 Med Rep Review Article Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in development of TB diagnostics and therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen development, and the new and repurposed anti-TB agents in clinical development. Faculty of 1000 Ltd 2012-06-01 /pmc/articles/PMC3370665/ /pubmed/22719795 http://dx.doi.org/10.3410/M4-12 Text en © 2012 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
spellingShingle | Review Article Swindells, Susan New drugs to treat tuberculosis |
title | New drugs to treat tuberculosis |
title_full | New drugs to treat tuberculosis |
title_fullStr | New drugs to treat tuberculosis |
title_full_unstemmed | New drugs to treat tuberculosis |
title_short | New drugs to treat tuberculosis |
title_sort | new drugs to treat tuberculosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370665/ https://www.ncbi.nlm.nih.gov/pubmed/22719795 http://dx.doi.org/10.3410/M4-12 |
work_keys_str_mv | AT swindellssusan newdrugstotreattuberculosis |